ME Therapeutics Holdings, Inc. Cash Flow
TSE:METX's free cash flow for Q4 2024 was $-150.26K. For the 2024 fiscal year, TSE:METX's free cash flow was decreased by $-354.73K and operating cash flow was $-150.26K. See a summary of the company’s cash flow.